Abstract 104P
Background
Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. Cadonilimab (AK104) is a bispecific antibody targeting PD-1 and CTLA-4 simultaneously. Here, we reported the efficacy and safety of cadonilimab with or without single-agent chemotherapy as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy.
Methods
The study population derived from retrospectively analyzed data (08/2022-04/2024) of patients treated with cadonilimab as second- or later-line therapy for metastatic NSCLC at Affiliated Hospital of Guangdong Medical University. Baseline characteristics, treatment patterns, and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAEs) were analyzed.
Results
21 patients were enrolled, of which 11 (52.3%) received cadonilimab as a third or later line therapy. The median age was 66 years old (range: 54-87), 16 (76.2%) were male, 10 (47.6%) had ECOG PS 2 or 3, and 4 (19.0%) had brain metastasis. Among evaluable patients, 5 reached partial response (PR) and 9 were stable disease (SD). The ORR was 29.4% and DCR was 82.4%. The median PFS was 6.77 months (95% confidence interval: 5.28-8.27) and median OS was not mature. Three patients (14.3%) experienced grade≥3 TRAEs. The most common TRAEs (≥10%) included anemia (42.9%), hypoleukocytosis (28.6%), and aspartate aminotransferase increased (19.1%), hypothyroidism(14.3%), alanine aminotransferase increased(14.3%). No treatment-related deaths were reported.
Conclusions
This real-world analysis further confirmed the promising efficacy and safety of cadonilimab as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy. Further exploration is ongoing and the updated analysis in a larger population is expected in the future.
Legal entity responsible for the study
Hualin Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract